

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Enzalutamide for metastatic hormone-relapsed prostate cancer when chemotherapy is not yet clinically indicated

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

During scoping consultees raised the following as potential equalities issues:

- a. Prostate cancer is more common in people aged 60 years or older and people of African-Caribbean origin, and also that people from lower socio-economic backgrounds are less likely to survive prostate cancer than people from more affluent backgrounds.
- b. There is no bone health treatment pathway for prostate cancer as there is for breast and other cancers, and that this amounts to sex discrimination.

It was determined during scoping that issues relating to prevalence of a disease or condition between different age, cultural or socio-economic groups cannot be addressed in NICE technology appraisal guidance and that NICE would not restrict access to enzalutamide based on age ethnicity or socio-economic status. The appraisal considered the effect of enzalutamide on bone health (skeletal related events) and the effect on quality of life.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

Not applicable.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

It is stated in the summary of the Appraisal Committee's key considerations

that no equality issues were raised.

Approved by Associate Director (name): Elisabeth George

Date: 03 06 2015

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

A consultee suggested that men living with cancer have poorer access to cancer treatments than women, and poorer survival rates compared with men across Europe. These points were not considered to be equality issues relevant to the current appraisal; they cannot be addressed in NICE technology appraisal guidance and NICE needs to appraise each drug on its merit and within its marketing authorisation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Summary of Appraisal Committee's key conclusions states: no equalities issues were raised.

Approved by Centre or Programme Director (name): Meindert Boysen

Date:

